Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 Combination Therapy in Advanced Solid Tumors
NCT06895928Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A2102 in solid tumor (advanced stage), sponsored by Hengrui Therapeutics. Started Mar 2025; status: recruiting.
02
Drugs
SHR-A2102
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06895928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895928.